keynote-048: progression post next line for r/m hnscc
Published 4 years ago • 337 plays • Length 7:56Download video MP4
Download video MP3
Similar videos
-
7:03
lba8_pr - keynote-048: phase 3 study of first-line pembrolizumab in r/m hnscc
-
3:08
keynote-048: pembrolizumab monotherapy for frontline r/m hnscc
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
-
5:24
keynote048: first line pembrolizumab for r/m hnscc
-
2:45
final keynote-048 results with frontline pembrolizumab in recurrent/metastatic hnscc
-
1:16:37
building on the immunotherapy foundation for head and neck cancer
-
11:57
immunotherapy in hnscc
-
9:16
stage iii-iv head and neck squamous cell carcinomas (hnc)
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
1:18
keynote-048 trial
-
1:41
cancer procedure: ct guided injection of immunotherapy into squamous cell carcinoma of head and neck
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
1:58
dr. rischin on keynote-048 results in head and neck squamous cell carcinoma
-
2:18
comment on cetuximab versus cisplatin in hpv-positive patients & keynote-048 in r/m hnscc
-
1:41
ct guided injection of immunotherapy into a squamous cell carcinoma of the head and neck.
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
11:47
pembrolizumab in hnscc
-
5:48
the impact of systemic therapy and keynote-048 trial
-
0:55
dr. cohen on immunotherapy in head and neck squamous cell carcinoma
-
3:55
checkpoint inhibitors for recurrent hnscc
-
1:09
the future role of immunotherapy in head and neck cancers
-
3:30
key points for treatment of advanced hnscc